

Immune Globulin (IG) for Treatment of Hepatitis A

Recommendations for Preexposure^{††} Protection Against Hepatitis A Virus (HAV) by Age and Risk Group

Age Indication	Risk Category Health Status	Hepatitis A Vaccine	Immune Globulin (IG)
<6 mos	Healthy	No	0.1–0.2 mL/kg ^{§§}
6–11 mos	Healthy	1 dose ^{¶¶}	None
12 mos–40 yrs	Healthy	1 dose ^{***}	None
>40 yrs	Healthy	1 dose ^{***}	0.1–0.2mL/kg ^{§§,†††}
All ages	Immunocompromised or chronic liver disease	1 dose ^{***}	0.1–0.2 mL/kg ^{§§,†††}
>6 mos	Persons who elect not to receive vaccine or for whom vaccine is contraindicated ^{**}	No	0.1–0.2 mL/kg ^{§§}

^{††} Consider IG before travel for persons with special risk factors for either HAV infection or increased risk for complications in the event of exposure to HAV.

^{§§} 0.1 mL/kg for travel up to 1 month; 0.2 mL/kg for travel up to 2 months, 0.2mL/kg every 2 months for travel of ≥2 months' duration.

^{¶¶} This dose does not count toward the routine 2-dose series that is initiated at age 12 months.

^{***} For persons not previously vaccinated with HepA vaccine, administer dose as soon as travel is considered, and complete series according to routine schedule.

^{†††} Provider may administer IG based on their risk assessment.

COM-B71-VIGHA-V2 (3/29/19)

Recommendations for Post-exposure Prophylaxis of Hepatitis A Virus by Age and Risk Category

Age Indication	Risk Category Health Status	Hepatitis A Vaccine	Immune Globulin (IG)	Time Frame
<12 mos	Healthy	No	0.1 mL/kg*	Within 14 days of exposure
12 mos–40 yrs	Healthy	1 dose [†]	None	Within 14 days of exposure
>40 yrs	Healthy	1 dose [†]	0.1 mL/kg [§]	Within 14 days of exposure
≥12 mos	Immunocompromised or chronic liver disease	1 dose [†]	0.1 mL/kg [¶]	Within 14 days of exposure
≥12 mos	Vaccine Contraindicated	No	0.1mg/kg	Within 14 days of exposure

* Do not administer measles, mumps, and rubella vaccine for at least 3 months after receipt of IG.

[†] A 2nd dose is not required for postexposure prophylaxis; however, for long-term immunity, complete the hepatitis A vaccination series with a 2nd dose at least 6 months after the 1st dose.

[§] The provider's risk assessment should determine the need for IG administration. If the provider's risk assessment determines that both vaccine and IG are warranted, administer HepA vaccine and IG simultaneously at different anatomic sites

[¶] Administered vaccine and IG simultaneously at different anatomic sites.

** Life-threatening allergic reaction to a previous dose of hepatitis A vaccine, or allergy to any vaccine component.

Reference

Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep 2018;67:1216–1220. DOI: [dx.doi.org/10.15585/mmwr.mm6743a5](https://doi.org/10.15585/mmwr.mm6743a5). Accessed February 15, 2019 from www.cdc.gov/mmwr/volumes/67/wr/mm6743a5.htm